121 related articles for article (PubMed ID: 24258999)
1. The clinical use of PET/CT in the evaluation of melanoma.
Keu KV; Iagaru AH
Methods Mol Biol; 2014; 1102():553-80. PubMed ID: 24258999
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma.
Iagaru A; Quon A; Johnson D; Gambhir SS; McDougall IR
Mol Imaging Biol; 2007; 9(1):50-7. PubMed ID: 17051322
[TBL] [Abstract][Full Text] [Related]
3. 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?
Cobben DC; Jager PL; Elsinga PH; Maas B; Suurmeijer AJ; Hoekstra HJ
J Nucl Med; 2003 Dec; 44(12):1927-32. PubMed ID: 14660718
[TBL] [Abstract][Full Text] [Related]
4. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
5. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
7. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
Annunziata S; Laudicella R; Caobelli F; Pizzuto DA; Aimn Working Group Y
Curr Radiopharm; 2020; 13(1):6-13. PubMed ID: 31749438
[TBL] [Abstract][Full Text] [Related]
8. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients.
Brady MS; Akhurst T; Spanknebel K; Hilton S; Gonen M; Patel A; Larson S
Ann Surg Oncol; 2006 Apr; 13(4):525-32. PubMed ID: 16474909
[TBL] [Abstract][Full Text] [Related]
9. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma.
Pawlik TM; Erasmus JJ; Truong MT; Macapinlac H; Ross MI; Gershenwald JE
AJR Am J Roentgenol; 2006 Jul; 187(1):W117-9. PubMed ID: 16794124
[No Abstract] [Full Text] [Related]
10. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography scanning in malignant melanoma.
Tyler DS; Onaitis M; Kherani A; Hata A; Nicholson E; Keogan M; Fisher S; Coleman E; Seigler HF
Cancer; 2000 Sep; 89(5):1019-25. PubMed ID: 10964332
[TBL] [Abstract][Full Text] [Related]
12. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography in melanoma.
Bourgeois AC; Chang TT; Fish LM; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
15. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic imaging in dermatology: utility of PET-CT in cutaneous melanoma.
Sánchez-Sánchez R; Serrano-Falcón C; Rebollo Aguirre AC
Actas Dermosifiliogr; 2015; 106(1):29-34. PubMed ID: 24661948
[TBL] [Abstract][Full Text] [Related]
18. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
19. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of (18)F-FDG in oncology.
Nabi HA; Zubeldia JM
J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
